新冠變異突破性感染危機有解！ 研生生醫研發多種對抗新冠病毒變異株的人類抗體

研生生醫在今年年初(2022)，從新冠肺炎疫苗施打者血液中分離出一系列可對抗新冠病毒變異株的人類抗體。

AcadeMab makes its mark at 2022 BIO USA

Visitors to the 2022 BIO International Convention in San Diego check out at booth of AcadeMab Biomedical Inc. at the Taiwan Pavilionto market the products and seek new business opportunities.

Taiwan's AcadeMab develops groundbreaking therapy for COVID-19 Omicron variant with potent neutralizing efficacy

後疫情時代抗體藥物開發策略(直接影片)